Insulet Co. (NASDAQ:PODD) Shares Sold by Chicago Capital LLC

Chicago Capital LLC lowered its stake in shares of Insulet Co. (NASDAQ:PODD) by 2.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 162,877 shares of the medical instruments supplier’s stock after selling 4,361 shares during the quarter. Chicago Capital LLC owned about 0.23% of Insulet worth $32,869,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Orion Portfolio Solutions LLC raised its position in Insulet by 276.6% during the fourth quarter. Orion Portfolio Solutions LLC now owns 10,221 shares of the medical instruments supplier’s stock valued at $2,069,000 after acquiring an additional 7,507 shares in the last quarter. Diversified Trust Co increased its holdings in shares of Insulet by 90.9% during the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock valued at $1,842,000 after purchasing an additional 4,348 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Insulet by 349.3% in the 1st quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock valued at $5,069,000 after purchasing an additional 22,993 shares during the period. Allianz Asset Management GmbH boosted its holdings in Insulet by 85.1% during the fourth quarter. Allianz Asset Management GmbH now owns 108,109 shares of the medical instruments supplier’s stock worth $23,457,000 after buying an additional 49,715 shares in the last quarter. Finally, Duality Advisers LP grew its position in Insulet by 89.4% during the first quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock valued at $3,279,000 after buying an additional 9,029 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. OTR Global restated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Redburn Atlantic initiated coverage on Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 price target on the stock. Barclays raised their price objective on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $234.00 target price on shares of Insulet in a research report on Tuesday, July 23rd. Finally, BTIG Research dropped their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $225.29.

Insider Activity at Insulet

In related news, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the sale, the senior vice president now owns 14,375 shares in the company, valued at $2,737,431.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the transaction, the director now directly owns 35,586 shares in the company, valued at approximately $6,779,488.86. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the sale, the senior vice president now directly owns 14,375 shares in the company, valued at $2,737,431.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,631 shares of company stock valued at $2,039,316. 0.47% of the stock is owned by insiders.

Insulet Stock Performance

PODD traded down $1.36 on Friday, hitting $214.75. 559,605 shares of the company traded hands, compared to its average volume of 835,722. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The company has a 50 day moving average of $196.15 and a 200-day moving average of $184.32. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $223.56. The stock has a market capitalization of $15.04 billion, a PE ratio of 65.08, a PEG ratio of 3.79 and a beta of 1.21.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.38 earnings per share. Sell-side analysts anticipate that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.